首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1918245

灰指甲市場－2026-2031年預測

Onychomycosis Market - Forecast from 2026 to 2031

出版日期: 2026年01月19日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計灰指甲市場將從 2025 年的 47.33 億美元成長到 2031 年的 61.36 億美元，複合年成長率為 4.42%。

由於影響手指甲和腳指甲的傳染性疾病——甲癬——的盛行率不斷上升，以及對先進診斷和治療方案的需求日益成長，灰指甲市場正經歷快速成長。該市場涉及影響指甲的真菌感染疾病的診斷、治療和管理，多家公司正投資開發新的治療方法方法。隨著人們對該疾病的認知不斷提高，以及先進診斷和治療方案的廣泛應用，預計未來幾年該市場將保持顯著的價值。

市場定義與臨床框架

灰指甲是指影響手指甲和腳趾甲的真菌感染疾病。由於甲癬盛行率不斷上升以及先進的診斷和治療方法的不斷發展，灰指甲治療市場正在快速成長。該市場可按類型、診斷和治療進行細分，從而為不同患者群體提供全面的疾病管理方案。

各公司正致力於研發創新抗真菌療法，旨在提高治療效果和改善患者預後。然而，新藥和療法核准的嚴格監管要求可能導致研發週期延長，上市成本增加，對市場成長產生負面影響。儘管面臨這些監管挑戰，但只要未被滿足的需求持續推動創新和投資，整體市場成長動能預計仍將保持強勁。

市場成長促進因素

患病率的上升是推動市場發展的主要因素之一。灰指甲盛行率的不斷成長，促使人們對尖端分析技術和治療方案的需求日益增加。這種疾病在已開發國家和發展中國家普遍存在，其發病率的上升也促使不同地區和患者群體對先進的診斷和治療方案產生濃厚的興趣。

技術創新是市場發展的主要驅動力。先進診斷和治療方法的進步正在推動灰指甲市場的成長。雷射治療和動態療法等技術的出現提高了治療效果，並縮短了治療時間。這些先進治療方法為傳統抗真菌藥物提供了替代方案，從而改善了對常規治療反應不佳的患者的治療效果。

提高公眾意識和開展教育活動正在拓展市場機會。人們對灰指甲及其症狀的認知不斷提高，推動了對診斷和治療方案的興趣。教育資源的普及和宣傳宣傳活動的發展，提高了人們對該疾病的了解，並減少了相關的社會歧視。隨著患者對灰指甲及其治療方法的了解不斷加深，他們更有可能尋求醫療協助，從而提高診斷率和治療率，進而推動市場成長。

人口老化是推動市場擴張的重要因素。老年人更容易感染灰指甲，而老年人口的成長也促進了市場成長。老年族群中灰指甲的盛行率較高，且常伴隨糖尿病和周邊血管疾病等併發症，這些疾病會增加感染風險。北美市場正因老年人口的成長和人們對感染疾病認知的提升而不斷擴大，而這個人口結構被認為是推動市場成長的關鍵因素。

社會心理和情緒影響是關鍵的市場促進因素。灰指甲引起的社會心理和心理影響廣泛存在，並可能顯著影響患者的生活品質。此疾病對生活品質的影響推動了對能夠改善患者身心健康的有效治療方案的需求。人們逐漸認知到，灰指甲的影響不僅限於身體症狀，還會影響心理健康和社會功能，這促使患者和醫療保健提供者尋求更有效的治療方法。

治療方法創新與發展

大型製藥公司正透過創新方法推動治療方案的研發。例如，Almirall公司提供的Terbinafine指甲溶液等療法已在臨床試驗中證實有效，預計將在未來幾年成為主要產品。 Onycho Pharma公司正在開發AMYCOT，這是一種高效的天然產品，用於治療灰指甲。本產品採用取得專利的生物活性濃縮技術，從藍菌菌株Altrospira maxima中萃取抗真菌成分。

Hexima公司正在開發一類新型抗真菌胜肽，該類胜肽對多種真菌具有頻譜活性。這些胜肽安全有效，有望成為灰指甲的突破性進展。這些創新療法體現了業界致力於透過全新的作用機制和更優的治療效果來滿足未被滿足的醫療需求的決心。

細分市場分析

由於診斷技術的進步和標靶治療的發展，白色表淺性灰指甲的病例數量正在迅速成長。白色表淺性灰指甲是一種亞型，其特徵是受累指甲表面出現白色粉狀沉積物。這種亞型是由於真菌直接侵入指甲表面而引起的，可以用刮器或旋轉磨鑽輕鬆去除。

由於免疫力缺乏低下患者增多以及人們對真菌性甲感染疾病的認知和診斷水平提高，淺表性白灰指甲的發病率正在迅速成長。灰指甲最常見的臨床亞型是遠端甲灰指甲，其表現為甲下角化過度或遠端部分指甲分離伴隨指甲碎裂。

區域市場趨勢

由於藥品價格高昂、人口老化加劇以及灰指甲率上升，北美預計將佔據顯著的市場佔有率。該地區對灰指甲治療藥物巨大潛力的認知不斷提高，正在推動市場擴張。北美地區對灰指甲的認知和診斷水平的提高，促進了市場成長，使該地區成為灰指甲治療和診斷領域領先的全球市場。

本報告的主要優勢：

深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要企業的策略舉措，並了解透過正確的策略進入市場的可能性。
市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
可操作的建議：利用這些見解，在快速變化的環境中製定策略決策，發展新的商業機會和收入來源。
受眾廣泛：對Start-Ups、研究機構、顧問公司、中小企業和大型企業都很有用且經濟實惠。

本報告的使用範例

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2021年至2025年的歷史數據和2026年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區分類的收入和預測評估，包括國家/地區
公司概況（策略、產品、財務資訊）、重大發展等。

The onychomycosis market is experiencing rapid growth driven by increasing prevalence of this contagious disease affecting finger and toe nails, along with rising demand for advanced diagnostic and treatment solutions. The market deals with diagnosis, treatment, and management of fungal infections affecting nails, with several companies investing in development of new treatments and therapies. The market is expected to hold significant value in coming years as increasing awareness about the condition and availability of advanced diagnostic and treatment options drive expansion.

Market Definition and Clinical Framework

Onychomycosis represents a fungal infection that influences the nails of fingers and toes. The onychomycosis treatment market is growing rapidly due to rising prevalence and development of advanced diagnostic and treatment methods. The market can be segmented by type, diagnosis, and treatment, providing comprehensive approaches to managing this condition across diverse patient populations.

Companies are developing innovative antifungal therapies to improve treatment efficacy and patient outcomes. However, stringent regulatory requirements for approval of new drugs and therapies may negatively impact market growth by extending development timelines and increasing costs associated with bringing new treatments to market. Despite these regulatory challenges, the overall market trajectory remains positive as unmet medical needs continue driving innovation and investment.

Market Growth Catalysts

Increasing prevalence represents one of the essential drivers of the market. The rising pervasiveness of onychomycosis is driving demand for cutting-edge analytics and treatment choices. The condition is normal in both created and non-industrial nations, with rising occurrence of the disease driving interest in advanced diagnostic and treatment options across diverse geographic regions and patient demographics.

Technological advancements are propelling market development significantly. The improvement of cutting-edge demonstrative and treatment choices is driving onychomycosis market growth. The accessibility of innovations, such as laser treatment and photodynamic treatment, is working on the adequacy of treatment and diminishing time expected for treatment. These advanced therapeutic modalities provide alternatives to traditional antifungal medications, offering improved outcomes for patients who may not respond adequately to conventional treatments.

Awareness and education initiatives are expanding market opportunities. The rising mindfulness about onychomycosis and its side effects are driving interest in demonstrative and treatment choices. The accessibility of instructive assets and mindfulness crusades is assisting with expanding mindfulness about the condition and diminishing disgrace related to it. As patients become more informed about fungal nail infections and available treatment options, they are more likely to seek medical care, driving market growth through increased diagnosis and treatment rates.

Aging population dynamics are contributing substantially to market expansion. The maturing populace is more defenseless to onychomycosis, with rising numbers of old individuals driving market development. The predominance of onychomycosis in old individuals is confounded by illnesses, for example, diabetes and fringe vascular sickness, which increment the gamble of contamination. The North American market is expanding due to rising geriatric population and higher infection awareness, positioning this demographic as a key growth driver.

Psychosocial and emotional effects represent important market drivers. The psychosocial and profound impacts coming about because of onychomycosis are far-reaching and may fundamentally affect personal satisfaction. The effect of the condition on personal satisfaction is driving interest in compelling treatment choices that can further develop physical and close-to-home prosperity of patients. Recognition that onychomycosis extends beyond purely physical symptoms to affect psychological wellbeing and social functioning is motivating both patients and healthcare providers to pursue more effective treatments.

Treatment Innovation and Development

Major pharmaceutical companies are advancing therapeutic options through innovative approaches. Almirall offers treatments including terbinafine nail solutions that have proven effective in clinical trials and are expected to be key products in coming years. Onycho Pharma is developing AMYCOT, a profoundly effectual normally inferred item to treat onychomycosis utilizing licensed bioactive concentrate detailing to outfit counter parasitic properties from cyanobacteria strain Arthrospira Maxima.

Hexima is developing a new class of antifungal peptides with broad-spectrum activity against fungal species. The peptides are designed to be safe and effective and have potential to represent significant advances in onychomycosis treatment. These innovative therapeutic approaches demonstrate industry commitment to addressing unmet medical needs through novel mechanisms of action and improved therapeutic profiles.

Segment Analysis

The white superficial onychomycosis segment is witnessing rapid growth from improved detection and targeted therapies. White superficial onychomycosis is a subtype characterized by white chalky deposits on the surface of affected nail plates. This subtype is caused by direct invasion of nail plate surface by fungus and can be easily scraped away with curette or rotary burr.

The white superficial onychomycosis segment is experiencing rapid growth due to increasing incidence of immunocompromised conditions and rising awareness and diagnosis of fungal nail infections. The most common clinical subtype of onychomycosis is distal lateral subungual onychomycosis, which presents as partial distal onycholysis with subungual hyperkeratosis or crumbling.

Regional Market Leadership

The North American region is expected to hold significant market share due to high drug costs, rising geriatric population, and increasing incidence of fungal nail infections. The region has seen growing awareness of vast potential of onychomycosis drugs, fueling market expansion. Rising awareness and diagnosis of fungal nail infections in North America are contributing to market growth, positioning the region as a key geographic market for onychomycosis treatments and diagnostics.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Onychomycosis Market Segmentation

By Type
Distal Subungual Onychomycosis
White Superficial Onychomycosis
Proximal Subungual Onychomycosis
Others
By Treatment Type
Oral
Topical
Others
By Distribution Channel
Institutional Sales
Retail Sales
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
India
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ONYCHOMYCOSIS MARKET BY TYPE

5.1. Introduction
5.2. Distal Subungual Onychomycosis
5.3. White Superficial Onychomycosis
5.4. Proximal Subungual Onychomycosis
5.5. Others

6. ONYCHOMYCOSIS MARKET BY TREATMENT TYPE

6.1. Introduction
6.2. Oral
6.3. Topical
6.4. Others

7. ONYCHOMYCOSIS MARKET BY DISTRIBUTION CHANNEL

7.1. Introduction
7.2. Institutional Sales
7.3. Retail Sales

8. ONYCHOMYCOSIS MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. Japan
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others